To test the effect of different doses of Rapatar on PCa tumorigenesis, we treated groups of male psPten–/– mice with either 25 mg/kg (dose that slowed down tumor progression in p53–/– mice [32] or with a lower dose of 5 mg/kg of Rapatar beginning at 26 weeks of age (n = 15/group). The gene discussed is TP53; the disease is posterior cortical atrophy.